{"id":"ondansetron-dexamethasone-aprepitant","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone. Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the central nervous system. Dexamethasone is a corticosteroid that provides additional antiemetic effects through multiple mechanisms. Together, these agents target complementary pathways to provide comprehensive CINV prevention.","oneSentence":"This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different molecular pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:25.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT07455955","phase":"PHASE2","title":"Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-06-03","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT06007586","phase":"PHASE3","title":"Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients","status":"COMPLETED","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2024-05-31","conditions":"Gynecological Tumor, Ovarian Cancer, Cervical Cancer","enrollment":143},{"nctId":"NCT04606264","phase":"PHASE3","title":"Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data","status":"COMPLETED","sponsor":"Jennifer Holder-Murray","startDate":"2023-05-15","conditions":"Perioperative Optimization","enrollment":2977},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT05189756","phase":"PHASE4","title":"Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-03-17","conditions":"Postoperative Nausea and Vomiting, Bariatric Surgery","enrollment":71},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT06080880","phase":"NA","title":"Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2023-12-01","conditions":"Nausea With Vomiting Chemotherapy-Induced","enrollment":98},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT03237611","phase":"PHASE2","title":"Low Dose Aprepitant for Patients Receiving Carboplatin","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-10-30","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":15},{"nctId":"NCT05772676","phase":"PHASE4","title":"The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting","status":"UNKNOWN","sponsor":"Hospital General Tlahuac","startDate":"2022-12-01","conditions":"Obesity, Nausea and Vomiting, Postoperative","enrollment":400},{"nctId":"NCT01298193","phase":"PHASE4","title":"Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2011-05","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05346731","phase":"PHASE3","title":"Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-04-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":210},{"nctId":"NCT02732015","phase":"PHASE2","title":"Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-12","conditions":"Locally Advanced Sarcoma","enrollment":37},{"nctId":"NCT00711555","phase":"PHASE2","title":"Emend for Multiple-day Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2005-11","conditions":"Nausea, Vomiting","enrollment":22},{"nctId":"NCT03079219","phase":"PHASE3","title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients","status":"COMPLETED","sponsor":"CCTU","startDate":"2017-03-23","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT01661335","phase":"PHASE3","title":"Efficacy of Aprepitant (Emend®) in Children","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2012-06-01","conditions":"Nausea, Vomiting, Childhood Cancer","enrollment":19},{"nctId":"NCT00588835","phase":"PHASE4","title":"Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2008-03","conditions":"Tumor","enrollment":20},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT03572829","phase":"PHASE2","title":"Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-03-01","conditions":"Vomiting, Nausea Post Chemotherapy, Head Neck Cancer","enrollment":44},{"nctId":"NCT02861859","phase":"PHASE3","title":"Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-12","conditions":"Breast Cancer","enrollment":221},{"nctId":"NCT03219710","phase":"PHASE3","title":"\"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)\"","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2017-07-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT03876938","phase":"PHASE3","title":"Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2019-03-01","conditions":"Antiemetic for Highly Emetogenic Chemotherapy","enrollment":147},{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":"Postoperative Nausea and Vomiting","enrollment":27034},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT00781768","phase":"PHASE4","title":"Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea","status":"COMPLETED","sponsor":"Loyola University","startDate":"2003-08","conditions":"Nausea, Vomiting","enrollment":181},{"nctId":"NCT03478605","phase":"PHASE2","title":"Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2018-05-25","conditions":"Emesis, Vomiting, Nausea Post Chemotherapy","enrollment":130},{"nctId":"NCT00871910","phase":"PHASE1","title":"Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-11","conditions":"Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma","enrollment":81},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT00619359","phase":"PHASE3","title":"Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":2322},{"nctId":"NCT00734929","phase":"PHASE4","title":"Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-09","conditions":"Postoperative Nausea and Vomiting","enrollment":115},{"nctId":"NCT01913990","phase":"PHASE4","title":"Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2011-09","conditions":"Emesis","enrollment":323},{"nctId":"NCT01205503","phase":"PHASE2","title":"Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release","status":"COMPLETED","sponsor":"Mara Chambers","startDate":"2010-09","conditions":"Breast Cancer, Non-Hodgkin's Lymphoma","enrollment":32},{"nctId":"NCT02357693","phase":"PHASE4","title":"Neurokinin Receptor Antagonist Associated to Ondansetron in PONV","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2015-02","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01111851","phase":"PHASE1","title":"Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":16},{"nctId":"NCT01402024","phase":"PHASE3","title":"Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2011-08","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":96},{"nctId":"NCT00080444","phase":"PHASE3","title":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":"Vomiting","enrollment":50},{"nctId":"NCT02021851","phase":"PHASE4","title":"Prevention of Nausea and Vomiting in Patients After Surgery","status":"COMPLETED","sponsor":"Yeditepe University Hospital","startDate":"2011-07","conditions":"Postoperative Nausea and Vomiting","enrollment":67},{"nctId":"NCT00738621","phase":"PHASE4","title":"Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients","status":"COMPLETED","sponsor":"Scott and White Hospital & Clinic","startDate":"2008-07","conditions":"Postoperative Nausea and Vomiting","enrollment":100},{"nctId":"NCT01474915","phase":"PHASE4","title":"Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting","status":"COMPLETED","sponsor":"Sergio Bergese","startDate":"2007-06","conditions":"Postoperative Nausea and Vomiting (PONV), Nausea","enrollment":122},{"nctId":"NCT01640340","phase":"NA","title":"Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2011-01","conditions":"Malignant Neoplasm","enrollment":40},{"nctId":"NCT00314743","phase":"EARLY_PHASE1","title":"Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2005-10","conditions":"Nausea, Vomiting","enrollment":48},{"nctId":"NCT01536691","phase":"PHASE3","title":"Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2011-06","conditions":"Cancer, Malignancy","enrollment":338},{"nctId":"NCT00169572","phase":"PHASE2","title":"Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":492}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aprepitant = Emend","ARM A"],"phase":"phase_3","status":"active","brandName":"Ondansetron, dexamethasone, aprepitant","genericName":"Ondansetron, dexamethasone, aprepitant","companyName":"University of Oklahoma","companyId":"university-of-oklahoma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different molecular pathways. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}